Plus Therapeutics Provides Updates on ReSPECT Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (GlobeNewswire) - Nov 19, 2022 - "In November 2022, Plus Therapeutics, in collaboration with Lurie Children's Hospital investigators, anticipates filing an Investigational New Drug (IND) application for a first-in-child Phase 1/2a clinical trial to determine the maximum tolerated dose, safety, tolerability and early efficacy of rhenium (186Re) obisbemeda in supratentorial recurrent or progressive pediatric ependymoma and high-grade glioma (HGG) in up to 24 patients initially."
IND • New P1/2 trial • Brain Cancer • CNS Tumor • Ependymoma • Glioma • Oncology • Solid Tumor
|